EMEKA OGWUDILE: Open Payments
NPI 1538690920 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$638 in 23 payments from 8 companies in 2025. Trend: 2023 $1,481 · 2024 $399 · 2025 $638
Food & beverage: $538Education: $100
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $148 |
| E.R. Squibb & Sons, L.L.C. | 2 | $133 |
| Supernus Pharmaceuticals, Inc. | 6 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $55 |
| ABBVIE INC. | 3 | $52 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
Products named: COBENFY, Qelbree, REXULTI, Auvelity, CAPLYTA, VRAYLAR, AUSTEDO XR, SPRAVATO.
Industry payments across MO — which companies pay providers there.
